Table 2.

Seroreactivity in association with benign condylomatous warts: Cumulative antibody responses to low risk (HPV-6, -11) or high risk (HPV-16, -18, -31) VLPs in HIV-positive versus HIV-negative men

Men with warts:	HIV-positive (n = 25,	HIV-negative (n = 55)
	including 9 homosexuals)
antibodies to low risk HPV	10 (40 %)+	14 (25.4 %)+
antibodies to high risk HPV	16 (64 %)*	7 (12.7 %)*
Heterosexuals without warts:	HIV-positive (n = 93)	HIV-negative (n = 98)
antibodies to low risk HPV	15 (16.1 %)	12 (12.2 %)
antibodies to high risk HPV	29 (31.1 %)**	11 (11.2 %)**
Homosexuals without warts:	HIV-positive (n = 50)	-
antibodies to low risk HPV	15 (30%)	-
antibodies to high risk HPV	21 (42%)	-
Male blood donors:	-	HIV-negative (n = 100, STD history unknown)
antibodies to low risk HPV	-	9 (9 %)
antibodies to high risk HPV	-	10 (10 %)

In HIV-positive men preferentially the high risk antibody prevalence is increased: ⁺ p = 0.2, *p < 0.0001, Odds ratio (95% CI), 12.2 (3.9–38.1); **p = 0.0007, Odds ratio (95%), 3.6 (1.7–7.7)